(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Disc Medicine's revenue in 2023 is $0.On average, 2 Wall Street analysts forecast IRON's revenue for 2026 to be $364,882,569, with the lowest IRON revenue forecast at $278,339,135, and the highest IRON revenue forecast at $451,426,004. On average, 4 Wall Street analysts forecast IRON's revenue for 2027 to be $1,663,999,702, with the lowest IRON revenue forecast at $755,595,396, and the highest IRON revenue forecast at $3,760,595,874.
In 2028, IRON is forecast to generate $3,855,129,790 in revenue, with the lowest revenue forecast at $3,075,490,527 and the highest revenue forecast at $5,144,083,803.